CoChat
Sign Up
Cited by 431Antifungal resistance and susceptibilityFungal Infections and StudiesImmunodeficiency and Autoimmune Disorders

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children

WALSH, THOMAS J., LUTSAR, IRJA, DRISCOLL, TIMOTHY, DUPONT, BERTRAND, RODEN, MAUREEN, GHAHRAMANI, PARVIS, HODGES, MICHAEL, GROLL, ANDREAS H., PERFECT, JOHN R.·2002·The Pediatric Infectious Disease Journal
DOI 10.1097/00006454-200203000-00015
Open this paper in CoChat — free account

Abstract

Objective To describe the safety and efficacy of voriconazole in children treated within the compassionate release program. Methods Children received voriconazole on a compassionate basis for treatment of an invasive fungal infection if they were refractory to or intolerant of conventional antifungal therapy. Voriconazole was administered as a loading dose of 6 mg/kg every 12 h i.v. on Day 1 followed by 4 mg/kg every 12 h i.v. thereafter. When feasible the route of administration of voriconazole was changed from i.v. to oral (100 or 200 mg twice a day for patients weighing or = 40 kg, respectively). Outcome was assessed by investigators at the end of therapy or at the last visit as success (complete or partial response), stable infection, or failure, based on protocol-defined criteria. Results Sixty-nine children (ages 9 months to 15 years; median, 7 years) received voriconazole; 58 had a proven or probable fungal infection. Among these 58 patients 27 had hematologic malignancies and 13 had chronic granulomatous disease as the most frequent underlying conditions. Forty-two patients had aspergillosis, 8 had scedosporiosis, 4 had invasive candidiasis and 4 had other invasive fungal infections. The median duration of voriconazole therapy was 93 days. At the end of therapy 26 patients (45%) had a complete or partial response. Four patients (7%) had a stable response, 25 (43%) failed therapy and 4 (7%) were discontinued from voriconazole because of intolerance. Success rates were…

Overview

Integrity signals

Registry

Crossref · 10.1097/00006454-200203000-00015

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 5

  1. Walsh, 1995, Adv Pediatr Infect Dis, 11, 187
  2. Viviani, 1998, Med Mycol, 36, 194
  3. Bomelburg, 1994, Hematol Blood Transf, 36, 778
  4. Ritter, 1995, Baillieres Clin Infect Dis, 2, 179
  5. Abbasi, 1999, Clin Infect Dis, 29, 1210, 10.1086/313445 · DOI

Cited by

Sorted by citations

See all 431

Related

See all

Metadata

Authors
WALSH, T. J., LUTSAR, I., DRISCOLL, T., DUPONT, B., RODEN, M., GHAHRAMANI, P., HODGES, M., GROLL, A. H., & PERFECT, J. R.
Affiliations
National Institutes of Health (US)
ORCID
Venue
The Pediatric Infectious Disease Journal
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2002-03
Volume
21
Issue
3
Pages
240-248
ISSN
0891-3668 (ISSN-L)
DOI
10.1097/00006454-200203000-00015
OpenAlex
W1986100989
Cited by
431
References
36
Citations by year
2026: 2 · 2025: 4 · 2024: 1 · 2023: 2 · 2022: 7 · 2021: 2 · 2020: 10 · 2019: 6 · 2018: 5 · 2017: 8 · 2016: 11 · 2015: 8 · 2014: 15 · 2013: 15 · 2012: 23
FWCI
24.50
Type
journal article
Language
en
Open access
closed
Locations
  • The Pediatric Infectious Disease Journal (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Keywords
voriconazole, invasive fungal infections, pediatric patients, aspergillosis, scedosporiosis, invasive candidiasis, chronic granulomatous disease, hematologic malignancies, refractory fungal infection, compassionate release, adverse drug reactions, hepatic transaminases, photosensitivity, treatment efficacy and safety, drug repurposing
MeSH terms
Adolescent, Antifungal Agents, Aspergillosis, Child, Child, Preschool, Drug Administration Schedule, Female, Granulomatous Disease, Chronic, Humans, Infant, Male, Mycoses, Pyrimidines, Triazoles, Treatment Failure, Hematologic Neoplasms, Voriconazole

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review